SCHEMBL1673523

SCHEMBL1673523

O=C(O)c1sc2cc(F)ccc2c1C1CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
RECQL P46063 1/20 0.50
UBE2M P61081 3/20 0.48
DCUN1D1 Q96GG9 3/20 0.48
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
HSD11B1 P28845 3/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ATM Q13315 1/20 0.47
PRSS12 P56730 4/20 0.47
BCKDK O14874 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7018371 0.85 BCKDK (0.49) LMNAALDH1A1RECQLRAB9APRSS12
SCHEMBL693361 0.83 BCKDK (0.60) LMNAALDH1A1RECQLNPC1RAB9A
SCHEMBL912876 0.83 KDM4E (0.49) LMNAALDH1A1RECQLHSD11B1MEN1
SCHEMBL2132126 0.81 ALDH1A1 (0.43) LMNAALDH1A1RECQLUBE2MDCUN1D1
SCHEMBL912482 0.81 ALDH1A1 (0.48) LMNAALDH1A1RECQLNPC1RAB9A
SCHEMBL2610281 0.81 BCKDK (0.57) LMNAALDH1A1RECQLNPC1RAB9A
SCHEMBL2130591 0.80 RAB9A (0.44) LMNAALDH1A1RECQLUBE2MDCUN1D1
SCHEMBL4792978 0.78 BCKDK (0.53) LMNAALDH1A1RECQLNPC1RAB9A
SCHEMBL1673484 0.78 MEN1 (0.51) ALDH1A1UBE2MDCUN1D1GAAGFER
SCHEMBL4767198 0.74 CTSS (0.53) LMNAALDH1A1RECQLRAB9ABCKDK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308854-A1 2,3,6-trisubstituted-4-pyrimidone derivatives Sanofi-Aventis (FR) 2011-04-13 EP disclosed
EP-2305651-A1 2,3,6-trisubstituted-4-pyrimidone derivatives Mitsubishi Tanabe Pharma Corporation (JP) 2011-04-06 EP disclosed
US-7504411-B2 2,3,6-Trisubstituted-4-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-17 US disclosed
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives SANOFI (FR) 2006-11-09 US disclosed
EP-1608630-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2005-12-28 EP disclosed
WO-2004085408-A1 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES MITSUBISHI PHARMA CORPORATION (JP) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252768-A1 2,3,6-Trisubstituted-4-pyrimidone derivatives PSEN1, PSEN2, MAPT LMNA 2558/4885ALDH1A1 1533/4885RECQL 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.